Keyword: Novartis

Novartis has touted early success for its new eye drug Beovu, but an alert tying the drug to potential vision loss might cause docs to balk.

Merck & Co. joined the pack in 2018 by hiring Jim Scholefield as its first chief digital officer. Now, less than two years in, he's moving on.

In the second price-fixing plea deal in as many weeks, federal prosecutors snagged a veteran of Novartis' Sandoz unit on conspiracy charges.

The end is near for a Novartis site in the U.K., and the 400 workers there. The Swiss drugmaker will close the site this year unless a buyer is found.

Novartis has secured FDA priority review for MET inhibitor capmatinib, which could compete with Merck KGaA's tepotinib.

11 would-be blockbusters span several therapeutic areas, including CNS, oncology, hematology, inflammatory diseases and metabolic disorders.

Regeneron touts Eylea's multiple indications, established user experience and a newly launched prefilled injector as Novartis' rival Beovu enters.

To empower employees to take the initiative, Novartis has them learning new digital tools.

Novartis' Sandostatin has been on the U.S. market for 20 years, but it's tough to produce—and that has the drugmaker predicting a generics-free 2020.

In a rare move, HHS will allow Novartis to pay for travel and other out-of-pocket expenses for Medicare and Medicaid patients on CAR-T drug Kymriah.